Georgetown University Lombardi Comprehensive Cancer Center Support Grant

Georgetown University, Washington DC

Investigators

Linked publications, trials & patents

Abstract

The Georgetown Lombardi Comprehensive Cancer Center (LCCC) is the only National Cancer Institute (NCI)-designated Cancer Center headquartered in the District of Columbia (DC). LCCC was established 52 years ago by Georgetown University (GU) to impact the cancer burden in its catchment area (CA) through high-impact cancer research. In 1974, LCCC first received comprehensiveness status and in 2019 realized Consortium status with the John Theurer Cancer Center (JTCC) of Hackensack Meridian Health (HMH). LCCC’s vision is to impact our CA, the nation, and beyond by pushing scientific knowledge, creativity, and application; serving all with compassion and respect; and preparing individuals who will devote themselves to reducing the severity of cancer on the individual, family, and community through improved access to care. Louis Weiner, MD, a leading medical oncologist and translational scientist with expertise in immuno- oncology, has led LCCC since 2008. During the project period, Weiner led the development of a visionary Strategic Plan for the Consortium that emphasizes transdisciplinary collaboration and community impact around five unifying themes: (1) Translation; (2) Health Outcomes and Community Engagement; (3) Leadership in Clinical Research and Clinical Care; (4) Signature Training and Education; and (5) Organization and Resources. LCCC also (1) received unprecedented financial investments and commitments from GU, HMH and MedStar Health, its academic medical center partner; (2) appointed 5 new Associate Directors and 6 Program Co- Leaders, incorporating leadership across the Consortium; (3) infused additional funding and expanded efforts in Community Outreach and Engagement (COE) and Cancer Research Training and Education Coordination (CRTEC); (4) increased its membership, committees, leadership and other forms of representation; (5) reviewed and enhanced CCSG Programs and Shared Resources for greater scientific impact; and (6) promoted transdisciplinary collaboration and bidirectional engagement of the communities we serve. LCCC successfully executed a multi-year recruitment effort to increase Cancer Focus and research depth across the Consortium, while applying more rigorous methods to ensure cancer relevance; and expanded clinical trials capabilities including investigator-initiated trials across the Consortium. LCCC’s 109 members have a total of $38.7M in annual cancer-focused funding, of which $21.9M is peer-reviewed, including $13.8M (63%) from NCI, $6.4M (29%) from other National Institutes of Health (NIH) agencies, and $1.7M (8%) from other peer-reviewed sources. This represents a 61% increase in peer-reviewed funding and a 41% increase in NCI funding over the prior project period. LCCC Members published 975 peer-reviewed papers in the first 4 years of the current project period, of which 29% were high-impact (≥10). During the project period 5783 patients have accrued (through 12/31/22) to interventional trials.